Effect of Sirolimus on Left Ventricular Hypertrophy in Kidney Transplant Recipients: A 1-Year Nonrandomized Controlled Trial

American Journal of Kidney Diseases

Volumn 52, Issue 2, 2008, Pages 324-330

  Paoletti, Ernesto ^a   Amidone, Marco ^a   Cassottana, Paolo ^a   Gherzi, Maurizio ^a   Marsano, Luigina ^a   Cannella, Giuseppe ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

calcineurin inhibitors; Left ventricular hypertrophy (LVH); renal transplant recipients; sirolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; CYCLOSPORIN; DIURETIC AGENT; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN; RAPAMYCIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; FEMALE; GRAFT RECIPIENT; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MALE; POPULATION RESEARCH; PROTEINURIA; SAMPLE SIZE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 47349128927     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.04.018     Document Type: Article

References (23)

1. Rigatto C., Foley R.N., Jeffery J., et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14 (2003) 462-468
2. Hernandez D., Lacalzada J., Salido E., et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 58 (2000) 889-897
3. Midtvedt K., Ihlen H., Hartmann A., et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: A prospective randomized double-blind study. Transplantation 72 (2001) 107-111
4. Paoletti E., Cassottana P., Amidone M., Gherzi M., Rolla D., and Cannella G. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: A randomized clinical trial. Am J Kidney Dis 50 (2007) 133-142
5. Shioi T., McMullen J.R., Tarnavski O., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107 (2003) 1664-1670
6. McMullen J.R., Sherwood M.C., Tarnavski O., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109 (2004) 3050-3055
7. Gao X.M., Wong G., Wang B., et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 24 (2006) 1663-1670
8. Liptak P., and Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allograft. Nat Clin Pract Nephrol 2 (2006) 398-404
9. Ruiz J.C., Campistol J.M., Grinyo J.M., et al. Early cyclosporine A withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 78 (2004) 1312-1318
10. Stallone G., Infante B., Schena A., et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 16 (2005) 3755-3762
11. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 18 (2005) 22-28
12. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
13. Sahn D.J., De Maria A., Kisslo J., et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
14. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necroscopy findings. Am J Cardiol 57 (1986) 450-458
15. Zoccali C., Benedetto F.A., Mallamaci F., et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12 (2001) 2768-2774
16. Ferrara L.A., Vaccaro O., Cardoni O., et al. Indexation criteria of left ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 18 (2005) 1263-1265
17. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
18. Levey A.S., Greene T., Kusek J.W., et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 A0828 (2000) (abstr)
19. Cannella G., Paoletti E., Delfino R., Peloso G.C., Molinari S., and Traverso G.B. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44 (1993) 881-886
20. Boluyt M.O., Li Z.B., Loyd A.M., Scalia A.F., Cirrincione G.M., and Jackson R.R. The mTOR/p70S6K signaling transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther 18 (2004) 257-267
21. Sadoshima J., and Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 77 (1995) 1040-1052
22. Amann K., and Tyralla K. Cardiovascular changes in chronic renal failure-Pathogenesis and therapy. Clin Nephrol 58 suppl 1 (2002) S62-S72
23. Mark P.B., Johnston N., Groenning B.A., et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69 (2006) 1839-1845